

# Tryptophan 2,3 Dioxygenase - Pipeline Review, H2 2019

<https://marketpublishers.com/r/TADAE8102187EN.html>

Date: December 2019

Pages: 40

Price: US\$ 3,500.00 (Single User License)

ID: TADAE8102187EN

## Abstracts

Tryptophan 2,3 Dioxygenase - Pipeline Review, H2 2019

### SUMMARY

According to the recently published report 'Tryptophan 2,3 Dioxygenase - Pipeline Review, H2 2019'; Tryptophan 2,3 Dioxygenase (Tryptamin 2,3 Dioxygenase or Tryptophan Oxygenase or Tryptophan Pyrrolase or Tryptophanase or TDO2 or EC 1.13.11.11) pipeline Target constitutes close to 11 molecules.

Tryptophan 2,3 Dioxygenase (Tryptamin 2,3 Dioxygenase or Tryptophan Oxygenase or Tryptophan Pyrrolase or Tryptophanase or TDO2 or EC 1.13.11.11) - Tryptophan 2, 3-dioxygenase is an enzyme that plays a critical role in tryptophan metabolism by catalyzing the first and rate-limiting step of the kynurenine pathway. It has specificity towards tryptamine and derivatives including D- and L-tryptophan, 5-hydroxytryptophan and serotonin.

The report 'Tryptophan 2,3 Dioxygenase - Pipeline Review, H2 2019' outlays comprehensive information on the Tryptophan 2,3 Dioxygenase (Tryptamin 2,3 Dioxygenase or Tryptophan Oxygenase or Tryptophan Pyrrolase or Tryptophanase or TDO2 or EC 1.13.11.11) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type; that are being developed by Companies / Universities.

It also reviews key players involved in Tryptophan 2,3 Dioxygenase (Tryptamin 2,3 Dioxygenase or Tryptophan Oxygenase or Tryptophan Pyrrolase or Tryptophanase or TDO2 or EC 1.13.11.11) targeted therapeutics development with respective active and

dormant or discontinued projects. Currently, The molecules developed by companies in Phase I, Preclinical and Discovery stages are 3, 7 and 1 respectively. Report covers products from therapy areas Oncology and Central Nervous System which include indications Melanoma, Solid Tumor, Bladder Cancer, Colon Carcinoma, Glioblastoma Multiforme (GBM), Head And Neck Cancer, Kidney Cancer (Renal Cell Cancer), Lung Cancer, Metastatic Melanoma, Non-Small Cell Lung Cancer and Parkinson's Disease.

## SCOPE

The report provides a snapshot of the global therapeutic landscape for Tryptophan 2,3 Dioxygenase (Tryptamin 2,3 Dioxygenase or Tryptophan Oxygenase or Tryptophan Pyrrolase or Tryptophanase or TDO2 or EC 1.13.11.11)

The report reviews Tryptophan 2,3 Dioxygenase (Tryptamin 2,3 Dioxygenase or Tryptophan Oxygenase or Tryptophan Pyrrolase or Tryptophanase or TDO2 or EC 1.13.11.11) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved in Tryptophan 2,3 Dioxygenase (Tryptamin 2,3 Dioxygenase or Tryptophan Oxygenase or Tryptophan Pyrrolase or Tryptophanase or TDO2 or EC 1.13.11.11) targeted therapeutics and enlists all their major and minor projects

The report assesses Tryptophan 2,3 Dioxygenase (Tryptamin 2,3 Dioxygenase or Tryptophan Oxygenase or Tryptophan Pyrrolase or Tryptophanase or TDO2 or EC 1.13.11.11) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news and deals related to Tryptophan 2,3 Dioxygenase (Tryptamin 2,3 Dioxygenase or Tryptophan Oxygenase or Tryptophan Pyrrolase or Tryptophanase or TDO2 or EC 1.13.11.11) targeted therapeutics

## **REASONS TO BUY**

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand the targeted therapy areas and indications for Tryptophan 2,3 Dioxygenase (Tryptamin 2,3 Dioxygenase or Tryptophan Oxygenase or Tryptophan Pyrrolase or Tryptophanase or TDO2 or EC 1.13.11.11)

Identify the use of drugs for target identification and drug repurposing

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Tryptophan 2,3 Dioxygenase (Tryptamin 2,3 Dioxygenase or Tryptophan Oxygenase or Tryptophan Pyrrolase or Tryptophanase or TDO2 or EC 1.13.11.11) development landscape

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

## Contents

Introduction

Global Markets Direct Report Coverage

Tryptophan 2,3 Dioxygenase (Tryptamin 2,3 Dioxygenase or Tryptophan Oxygenase or Tryptophan Pyrrolase or Tryptophanase or TDO2 or EC 1.13.11.11) - Overview

Tryptophan 2,3 Dioxygenase (Tryptamin 2,3 Dioxygenase or Tryptophan Oxygenase or Tryptophan Pyrrolase or Tryptophanase or TDO2 or EC 1.13.11.11) - Therapeutics

Development

Products under Development by Stage of Development

Products under Development by Therapy Area

Products under Development by Indication

Products under Development by Companies

Tryptophan 2,3 Dioxygenase (Tryptamin 2,3 Dioxygenase or Tryptophan Oxygenase or Tryptophan Pyrrolase or Tryptophanase or TDO2 or EC 1.13.11.11) - Therapeutics

Assessment

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Tryptophan 2,3 Dioxygenase (Tryptamin 2,3 Dioxygenase or Tryptophan Oxygenase or Tryptophan Pyrrolase or Tryptophanase or TDO2 or EC 1.13.11.11) - Companies

Involved in Therapeutics Development

CanBas Co Ltd

Emcure Pharmaceuticals Ltd

F. Hoffmann-La Roche Ltd

Jiangsu Hengrui Medicine Co Ltd

Luye Pharma Group Ltd

Merck & Co Inc

Netherlands Translational Research Center BV

NewLink Genetics Corp

Shanghai De Novo Pharmatech Co Ltd

Syntekabio Inc

Tryptophan 2,3 Dioxygenase (Tryptamin 2,3 Dioxygenase or Tryptophan Oxygenase or Tryptophan Pyrrolase or Tryptophanase or TDO2 or EC 1.13.11.11) - Drug Profiles

DN-1406131 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

EPL-1410 - Drug Profile

Product Description  
Mechanism Of Action  
R&D Progress  
HTI-1090 - Drug Profile  
Product Description  
Mechanism Of Action  
R&D Progress  
LY-01013 - Drug Profile  
Product Description  
Mechanism Of Action  
R&D Progress  
Monoclonal Antibody to Inhibit IDO and TDO for Oncology - Drug Profile  
Product Description  
Mechanism Of Action  
R&D Progress  
RG-70099 - Drug Profile  
Product Description  
Mechanism Of Action  
R&D Progress  
Small Molecules to Inhibit IDO and TDO for Oncology - Drug Profile  
Product Description  
Mechanism Of Action  
R&D Progress  
Small Molecules to Inhibit IDO/TDO for Oncology - Drug Profile  
Product Description  
Mechanism Of Action  
R&D Progress  
Small Molecules to Inhibit TDO for Oncology - Drug Profile  
Product Description  
Mechanism Of Action  
R&D Progress  
Small Molecules to Inhibit TDO for Parkinson's Disease - Drug Profile  
Product Description  
Mechanism Of Action  
R&D Progress  
STB-001 - Drug Profile  
Product Description  
Mechanism Of Action  
R&D Progress

Tryptophan 2,3 Dioxygenase (Tryptamin 2,3 Dioxygenase or Tryptophan Oxygenase or Tryptophan Pyrrolase or Tryptophanase or TDO2 or EC 1.13.11.11) - Dormant Products  
Tryptophan 2,3 Dioxygenase (Tryptamin 2,3 Dioxygenase or Tryptophan Oxygenase or Tryptophan Pyrrolase or Tryptophanase or TDO2 or EC 1.13.11.11) - Product

Development Milestones

Featured News & Press Releases

Jul 31, 2018: Approval for clinical trial for class I new chemical drug—Anti-Tumor innovative drug (LY01013) in China

Jun 06, 2018: De Novo Pharmatech receives approval to initiate clinical trials in China with IDO1/TDO2 inhibitor DN1406131

Jan 05, 2018: De Novo Pharmatech submitted the IND application of DN1406131 to FDA

Dec 04, 2017: De Novo Pharmatech submitted the IND application of DN1406131 to CFDA

Feb 10, 2015: IOmet Pharma demonstrates superior in vivo PK/PD properties in pre-clinical IDO, TDO and Dual IDO/TDO cancer immunotherapy programs

Feb 06, 2015: IOmet Pharma to present data on pre-clinical cancer immunotherapy programs at Keystone Tumor Immunology Symposium

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

## List Of Tables

### LIST OF TABLES

Number of Products under Development by Stage of Development, H2 2019  
Number of Products under Development by Therapy Areas, H2 2019  
Number of Products under Development by Indication, H2 2019  
Number of Products under Development by Companies, H2 2019  
Products under Development by Companies, H2 2019  
Products under Development by Companies, H2 2019 (Contd..1), H2 2019  
Number of Products by Stage and Mechanism of Actions, H2 2019  
Number of Products by Stage and Route of Administration, H2 2019  
Number of Products by Stage and Molecule Type, H2 2019  
Pipeline by CanBas Co Ltd, H2 2019  
Pipeline by Emcure Pharmaceuticals Ltd, H2 2019  
Pipeline by F. Hoffmann-La Roche Ltd, H2 2019  
Pipeline by Jiangsu Hengrui Medicine Co Ltd, H2 2019  
Pipeline by Luye Pharma Group Ltd, H2 2019  
Pipeline by Merck & Co Inc, H2 2019  
Pipeline by Netherlands Translational Research Center BV, H2 2019  
Pipeline by NewLink Genetics Corp, H2 2019  
Pipeline by Shanghai De Novo Pharmatech Co Ltd, H2 2019  
Pipeline by Syntekabio Inc, H2 2019  
Dormant Projects, H2 2019

## List Of Figures

### LIST OF FIGURES

Number of Products under Development by Stage of Development, H2 2019

Number of Products under Development by Therapy Areas, H2 2019

Number of Products under Development by Top 10 Indications, H2 2019

Number of Products by Stage and Mechanism of Actions, H2 2019

Number of Products by Stage and Mechanism of Actions, H2 2019

Number of Products by Molecule Types, H2 2019

Number of Products by Stage and Molecule Types, H2 2019

### COMPANIES MENTIONED

CanBas Co Ltd

Emcure Pharmaceuticals Ltd

F. Hoffmann-La Roche Ltd

Jiangsu Hengrui Medicine Co Ltd

Luye Pharma Group Ltd

Merck & Co Inc

Netherlands Translational Research Center BV

NewLink Genetics Corp

Shanghai De Novo Pharmatech Co Ltd

Syntekabio Inc



## I would like to order

Product name: Tryptophan 2,3 Dioxygenase - Pipeline Review, H2 2019

Product link: <https://marketpublishers.com/r/TADAE8102187EN.html>

Price: US\$ 3,500.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

[info@marketpublishers.com](mailto:info@marketpublishers.com)

## Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/TADAE8102187EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:  
Last name:  
Email:  
Company:  
Address:  
City:  
Zip code:  
Country:  
Tel:  
Fax:  
Your message:

**\*\*All fields are required**

Customer signature \_\_\_\_\_

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970